Optimizing heart failure treatment following cardiac resynchronization therapy

ConclusionIn the present study, 38% of those who remained symptomatic 6  months after CRT implantation were eligible for optimization of medical therapy with sacubitril/valsartan, ivabradine, or both. Patients with CRT may benefit from systematic follow-up including evaluation of medical treatment.Graphic abstract
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research